2019 tables: Institutions - biological sciences - corporate

The 2019 tables are based on Nature Index data from 1 January 2018 to 31 December 2018.

Table criteria

Request a badge Export CSV
# Institution Share 2017 Share 2018 Count 2018 Change in Adjusted Share* 2017–2018
1 F. Hoffmann-La Roche AG, Switzerland 40.57 44.10 110 1.8%
2 Novartis International AG, Switzerland 30.96 27.30 93 -17.4%
3 AstraZeneca plc, United Kingdom (UK) 19.31 19.86 84 -3.7%
4 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 10.24 11.54 68 5.6%
5 Sanofi, France 3.60 3.63 27 -5.8%
6 Techint Group, Italy 2.11 2.65 13 17.7%
7 Novo Nordisk A/S, Denmark 4.12 1.96 14 -55.6%
8 Bayer AG, Germany 1.87 1.74 27 -12.9%
9 UCB S.A., Belgium 2.36 1.73 4 -31.2%
10 Merck KGaA, Germany 1.85 1.72 13 -12.9%
11 C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim), Germany 2.30 1.41 15 -42.7%
12 Sodercan, S.A., Spain 0.05 1.33 10 2513.0%
13 Oxford Nanopore Technologies Ltd., United Kingdom (UK) – 1.30 3 N/A
14 Royal Dutch Shell plc (Shell), Netherlands 0.83 1.19 3 34.7%
15 Siemens AG, Germany 0.54 1.11 10 92.0%
16 Earlham Institute (EI), United Kingdom (UK) 1.88 1.09 15 -45.5%
17 Nestlé S.A., Switzerland 2.25 1.07 8 -55.5%
18 Argenx SE, Belgium 0.05 1.06 2 2089.1%
19 Austrian Centre of Industrial Biotechnology (ACIB), Austria 0.18 1.05 3 434.5%
20 Science Europe AISBL, Belgium – 1.00 1 N/A
21 BASF SE, Germany 0.20 0.92 6 328.5%
22 Innate Pharma S.A., France 0.07 0.90 6 1169.7%
23 Merus N.V., Netherlands 0.43 0.88 2 92.5%
24 Servier Laboratories, France 0.44 0.83 4 76.9%
25 Genmab B.V., Netherlands 0.25 0.78 2 193.7%
26 Oryzon Genomics, Spain – 0.76 1 N/A
27 Alkermes plc, Ireland – 0.71 2 N/A
28 Genos Ltd., Croatia 0.46 0.67 3 37.2%
29 Ben-Ari Institute of Neuroarcheology, France – 0.67 1 N/A
30 BioNTech AG, Germany 1.49 0.66 6 -58.4%
31 BioMérieux SA, France – 0.63 2 N/A
32 Proteros Biostructures GmbH, Germany – 0.60 2 N/A
33 Immatics Biotechnologies GmbH, Germany 0.04 0.59 3 1231.6%
34 Monasterium Laboratory Skin and Hair Research Solutions GmbH, Germany – 0.59 2 N/A
35 Fimlab Laboratories Ltd., Finland 0.19 0.57 22 188.9%
36 Fibrostatin S.L., Spain – 0.56 1 N/A
37 IONTAS Ltd., United Kingdom (UK) – 0.53 1 N/A
38 Mutabilis, France – 0.53 1 N/A
39 Instituto Português de Oncologia de Lisboa (IPO Lisboa), Portugal – 0.51 2 N/A
40 Eurofins Scientific, Luxembourg 0.05 0.50 1 789.7%
40 Pisces Conservation Ltd., United Kingdom (UK) – 0.50 1 N/A
41 SyMO-Chem B.V., Netherlands – 0.45 2 N/A
42 EN-FIST Centre of Excellence, Slovenia 0.42 0.44 3 -1.3%
42 ProQR Therapeutics, Netherlands – 0.44 2 N/A
43 Surflay Nanotec GmbH, Germany – 0.43 1 N/A
44 Novozymes A/S, Denmark 0.50 0.41 2 -23.1%
45 Medtronic plc, Ireland 0.08 0.40 2 354.9%
45 ExpreS2ion Biotechnologies Aps, Denmark – 0.40 2 N/A
46 Deinobiotics SAS, France – 0.40 1 N/A
47 AZTI-Tecnalia, Spain 0.29 0.40 2 27.6%
48 SkylineDx B.V, Netherlands – 0.38 1 N/A
49 Cambridge Display Technology Ltd., United Kingdom (UK) – 0.36 1 N/A
50 Rijk Zwaan Zaadteelt en Zaadhandel B.V., Netherlands 0.04 0.33 1 649.2%
50 Hoekmine B.V., Netherlands – 0.33 1 N/A
50 CCP hf., Iceland – 0.33 1 N/A
50 Neurimmune Holding AG, Switzerland – 0.33 1 N/A
50 Nosopharm SAS, France – 0.33 1 N/A

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals through 2022, in 2023 64 health-science journals were added to the Index. The 146 journals in the Nature Index were selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at nature.com/nature-index/.
  5. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2022 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.


Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.